EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models

Alexia K Martin, Jack Hedberg, Ilse Hernandez-Aguirre, Uksha Saini, Doyeon Kim, Yeaseul Kim, Ravi Dhital, Kevin A Cassady

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2025-012227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Alexia K Martin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Glioma, CD8-Positive T-Lymphocytes, Oncolytic Virotherapy, Oncolytic Viruses. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH, CancerFree KIDS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Malignant gliomas (MGs) are the most common primary brain malignancies and are considered universally fatal. Oncolytic herpes simplex viruses (oHSVs) are promising immunotherapeutics capable of selectively lysing cancer cells, eliciting antitumor immunity, and providing local delivery of immune-activating transgenes. Interleukin 27 (IL-27) is a pleiotropic cytokine capable of enhancing tumor-reactive cytotoxic T lymphocyte (CTL) function while also possessing neuroprotective properties. We hypothesized that IL-27 expression by oHSV would enhance CTL function and improve antiglioma therapeutic activity.

Methods

We developed an oHSV that expresses IL-27 (C027). The antiglioma efficacy of C027 was tested in three syngeneic orthotopic glioma models derived from both chemical (CT-2A) and genetic (SB28, KR158) glioma lines. Spectral flow cytometry was used to assess immunophenotypic and functional changes in the tumor infiltrates and systemically. To further investigate the C027-related CTL activity, we employed in vivo cell-specific depletion and IL-27 blockade alongside in vitro T cell stimulation assays. Local and systemic antitumor memory was evaluated by both orthotopic and flank tumor rechallenge of C027-treated long-term survivors.

Results

C027 significantly prolonged survival in syngeneic orthotopic glioma models derived from both chemical (CT-2A) and genetic (KR158, SB28) glioma lines. In the CT-2A model, IL-27-expressing oHSV treatment was associated with increased intratumoral multifunctional effector CTLs and functional T cell populations systemically. Mechanistically, both CD8 T cells and IL-27 were required for the C027 survival benefit in vivo and IL-27 enhanced CTL function in vitro. C027-treated mice that survived their initial tumors had local and systemic antiglioma memory rejecting tumors on rechallenge.

Conclusions

Our findings demonstrate that IL-27 expression by oHSV significantly improves antiglioma therapeutic efficacy, enhances CTL effector function, and induces durable immune memory. Thus, IL-27-oHSV may provide a promising therapeutic approach for MGs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaCD8-Positive T-LymphocytesOncolytic VirotherapyOncolytic VirusesInterleukinsBrain NeoplasmsSimplexvirusInterleukin-27AnimalsMiceHumansCell Line, TumorDisease Models, AnimalFemaleMice, Inbred C57BL

Stichwörter der Autor:innen

Central Nervous System CancerCytokineImmunotherapyOncolytic virusT cell

Substanzen

InterleukinsInterleukin-27

Autor:innen und Institutionen

  • Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Medical Scientist Training Program, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA Kevin.Cassady@Nationwidechildrens.org.
  • Division of Pediatric Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio, USA.

Förderung

  • NCI NIH HHS
  • NIH
  • CancerFree KIDS
  • DOD

Zitieren

APA

Martin, A. K., Hedberg, J., Hernandez-Aguirre, I., Saini, U., Kim, D., Kim, Y., Dhital, R., & Cassady, K. A. (2025). Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012227

Vancouver

Martin AK, Hedberg J, Hernandez-Aguirre I, Saini U, Kim D, Kim Y, et al. Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-012227

BibTeX
@article{Martin2025,
  author = {Martin, Alexia K and Hedberg, Jack and Hernandez-Aguirre, Ilse and Saini, Uksha and Kim, Doyeon and Kim, Yeaseul and Dhital, Ravi and Cassady, Kevin A},
  title = {Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2025-012227}
}
Kostenlos starten →